U.S. Specialty Stores Stock News

Duke Energy (NYSE:DUK) has completed the sale of its Tennessee Piedmont Natural Gas business to Spire. The company plans to use the proceeds to support its regulated capital investment plan over the next five years. The move marks a shift in Duke Energy's portfolio toward grid and generation projects while aiming to manage customer costs. Duke Energy, trading at about $130.9 per share, is using this transaction to refine where its capital is focused. The company has delivered an 11.5%...

Coca-Cola plans a long term investment of $1 billion in South Africa to expand production and distribution capacity. The company is acquiring a majority stake in Coca-Cola Beverages Africa, covering South Africa and 14 additional African markets. The investment focuses on local hiring, operational expansion and deeper integration with regional partners over multiple years. Coca-Cola (NYSE: KO) is adding a major Africa focused chapter to its global story with this $1 billion commitment. The...

If you are wondering whether Alibaba Group Holding's share price offers value right now, or if the market is pricing it fairly, this breakdown will help you connect the current price with what the business may be worth. The stock last closed at US$123.73, with returns of a 4.7% decline over 7 days, a 13.2% decline over 30 days, a 20.6% decline year to date and a 3.1% decline over the past year, set against a 32.1% gain over 3 years and a 42.2% decline over 5 years. Recent headlines around...

In March 2026, Jabil Inc. reported second-quarter results showing year-on-year growth in sales and net income, and issued third-quarter guidance calling for net revenue between US$8.10 billion and US$8.90 billion, U.S. GAAP operating income of US$398 million to US$458 million, and diluted EPS of US$2.36 to US$2.76. The company also lifted its full-year fiscal 2026 outlook to US$34.00 billion in revenue, underscoring how healthcare exposure and injector-pen manufacturing for weight-loss drugs...

KULR Technology Group (KULR) closed FY 2025 with fourth quarter revenue of US$2.9 million and a basic EPS loss of US$0.97, alongside a trailing twelve month EPS loss of US$1.56 on revenue of US$16.2 million. Over the last few quarters, the company has reported revenue between US$2.4 million and US$6.9 million per quarter, while quarterly EPS has ranged from a loss of US$0.54 to a gain of US$0.22. This leaves investors focusing on how quickly these top line changes might translate into...

FitLife Brands (FTLF) has just closed out FY 2025 with fourth quarter revenue of US$25.9 million and basic EPS of US$0.17, alongside trailing twelve month revenue of US$81.5 million and EPS of US$0.68 that investors will be watching against the prior year’s figures. Over recent quarters the company has seen revenue move from US$15.0 million in Q4 FY 2024 to US$25.9 million in Q4 FY 2025, while quarterly EPS shifted from US$0.23 to US$0.17, setting the backdrop for the latest full year read on...

Check Point Software Technologies (CHKP) closed out FY 2025 with fourth quarter revenue of US$744.9 million and basic EPS of US$2.85, while full year trailing EPS reached US$9.85 on revenue of US$2.7 billion and earnings grew 25% over the past 12 months. Over the last few reported periods, revenue has moved from US$703.7 million in Q4 2024 to US$744.9 million in Q4 2025, with quarterly basic EPS ranging from US$1.77 in Q1 2025 to US$3.34 in Q3 2025 and trailing net income rising from US$845.7...

Dawson Geophysical (DWSN) closed out FY 2025 with fourth quarter revenue of US$26.9 million and basic EPS of US$0.02, alongside net income of US$0.6 million. This set a cleaner finish to a year where the trailing twelve month figures still show a loss of US$1.9 million on US$75.6 million of revenue and a basic EPS loss of US$0.06. Over recent quarters the company has seen quarterly revenue range from US$9.9 million to US$26.9 million, with EPS moving between a loss of US$0.08 and a profit of...

IDEAYA Biosciences (IDYA) recently reported the first patient enrolled in a Phase 1 trial combining IDE849, a DLL3 targeting antibody drug conjugate, with PARG inhibitor IDE161 in several DLL3 upregulated solid tumors. See our latest analysis for IDEAYA Biosciences. The Phase 1 combination update has come as IDEAYA’s share price has eased slightly in the short term, with a 7 day share price return of 3.47% and a 1 year total shareholder return close to 100%. This reflects how recent trial...

ABM Industries stock: recent returns and business mix in focus ABM Industries (ABM) has drawn investor attention after a one-month return of about a 13% decline, adding to a past three-month drop of roughly 9%. This performance has invited closer inspection of its fundamentals. See our latest analysis for ABM Industries. With the share price at $38.70, ABM Industries has seen weaker momentum recently, with a 30 day share price return of a 13.44% decline and a 1 year total shareholder return...

In late March 2026, UWM Holdings CEO Mat Ishbia and SFS Holding Corp sold 3,001,722 Class A shares, shortly after the company reported fourth-quarter 2025 revenue of US$945.00 million that exceeded forecasts and announced advisory and proxy work around its proposed acquisition of Two Harbors Investment Corp. This combination of insider selling, stronger-than-expected quarterly results, and an active acquisition process highlights a period of meaningful corporate change and heightened...

Silicon Motion Technology (NasdaqGS:SIMO) is expanding its automotive grade NAND storage controller portfolio for connected and AI focused vehicles. The company is aligning products with automotive safety and cybersecurity standards such as AEC-Q100, ISO 26262, ISO 21434, and ASPICE Level 3. Its embedded storage solutions are being tailored for advanced driver-assistance systems and autonomous driving platforms. For readers following NasdaqGS:SIMO, this push into automotive storage sits on...

Dianthus Therapeutics recently reported an early “GO” decision in its late-stage CAPTIVATE trial of claseprubart for chronic inflammatory demyelinating polyneuropathy, after meeting interim responder goals ahead of schedule. The US FDA also agreed to multiple company-proposed changes across claseprubart’s development program, including updated screening criteria, lab work, and autoimmune safety monitoring, potentially streamlining current and future studies. We’ll now examine how the early...

Hesai Group recently reported its fourth-quarter and full-year 2025 results, turning a prior-year loss into net income of CNY 435.88 million on CNY 3,027.57 million in sales, and entered a 2026 Supply of Products Framework Agreement under which it will provide LiDAR products and robotic actuators plus manufacturing and support services to Sharpa. By pairing improved profitability with a new Physical AI-focused partnership that bundles hardware and integration services, Hesai is broadening...

Arcutis Biotherapeutics (ARQT) is back in focus after new INTEGUMENT-INFANT Phase 2 data on ZORYVE cream 0.05% in infants with mild to moderate atopic dermatitis, supporting a planned supplemental New Drug Application. See our latest analysis for Arcutis Biotherapeutics. The new clinical data arrives after a mixed stretch for the shares, with a 1-day share price return of 10.45% and 7-day share price return of 7.92% contrasting with a 30-day share price return decline of 12.64%. However, a...

If you are wondering whether Aflac at around US$109.64 is offering fair value or a potential bargain, this article walks through what the current price might be indicating. The stock has been relatively steady recently, with a 2.3% return over the last 7 days, a 3.3% decline over 30 days, and returns of 0.5% decline year to date and 0.2% decline over 1 year, set against much stronger 3 year and 5 year returns of 81.6% and 137.7%. Recent coverage around Aflac has focused on its role as a...

Alkermes (NasdaqGS:ALKS) has begun Phase 3 clinical trials for alixorexton, its orexin 2 receptor agonist for narcolepsy type 1 and type 2. The late stage Brilliance Studies aim to evaluate alixorexton in patients with significant unmet treatment needs in sleep disorders. This marks a new development in Alkermes' pipeline beyond prior focus areas highlighted in earlier coverage. For Alkermes, known for its work in neuroscience and psychiatry, the Brilliance Studies add a new dimension to...

EQT (NYSE:EQT) is advancing its post Olympus Energy integration by preparing multi bench drilling across the Marcellus and Utica formations. The company is conducting field surveys in Upper Burrell, Pennsylvania, as it plans new lateral wells in previously untapped areas. This shift marks a move away from a single target drilling approach toward broader development of its Appalachian acreage. EQT, trading at $61.09, is entering this next phase after a period where attention largely centered...

Advanced Energy Industries (AEIS) has drawn investor attention after a strong past 3 months, with total return around 54% and one year total return near 240%, prompting closer review of its fundamentals. See our latest analysis for Advanced Energy Industries. After a sharp run over the past year, with 1 year total shareholder return close to 240% and a 90 day share price return of about 54%, momentum has cooled in the last month, even though the share price closed at US$322.71 after an 8.2% 1...

LTC Properties (LTC), a real estate investment trust focused on seniors housing and health care properties, has been drawing attention as investors reassess its recent share performance and income profile following recent price moves. See our latest analysis for LTC Properties. The recent pullback, with a 1 month share price return showing a 6.35% decline from US$37.16, comes after a stronger run where the 3 year total shareholder return sits at 36.68%. This suggests that momentum has cooled...

A securities class action lawsuit was recently filed against Solaris Energy Infrastructure, Inc., alleging that between July 9, 2024 and March 17, 2025 the company misled investors about the prospects of its Mobile Energy Rentals LLC acquisition and overstated profitability metrics. The case raises questions about Solaris’s disclosure practices and financial reporting around a key acquisition, introducing potential legal, financial, and reputational risks for existing and prospective...

If you are wondering whether Philip Morris International is priced attractively at its current level, the key question is how its share price lines up with the value of its cash flows and assets. The stock last closed at US$165.34, with returns of 0.9% over 7 days, an 11.5% decline over 30 days, 3.1% year to date and 8.3% over the past year. These figures can change how investors think about both growth potential and risk. Recent news coverage has focused on Philip Morris International's...

Infinity Natural Resources (INR) has been drawing attention after recent trading swings, with the stock showing a mix of short term volatility and longer term moves that have left recent returns uneven for investors. See our latest analysis for Infinity Natural Resources. The recent pullback, with a 1 day share price return of a 4.55% decline to US$17.61, comes after a 19.55% 90 day share price return and a softer 1 year total shareholder return of a 4.81% decline. This suggests momentum has...

Why InterDigital stock is back on investor radar InterDigital (IDCC) is in focus after securing a preliminary injunction in Brazil against Transsion over alleged 5G patent infringement, a decision that directly affects device shipments in an important smartphone market. See our latest analysis for InterDigital. The injunction news follows a weaker 30-day share price return of a 17.6% decline and a year-to-date share price return of a 7.4% decline, set against a 1-year total shareholder return...